Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Monday announced the the re availability of Zenatane (Isotretinoin Capsules, USP) in 10 mg, 20 mg, 30 mg and 40 mg following approval by the US Food and Drug Administration (USFDA) to treat severe acne as well as prevent certain skin cancers.
The Zenatane (Isotretinoin Capsules, USP) in 10 mg, 20 mg, 30 mg and 40 mg is reportedly the therapeutic equivalent generic version of Accutane and is being launched under an approved Risk Evaluation and Mitigation Strategy (REMS) Programme as well as the US FDA's special restricted iPLEDGE distribution programme.
For the most recent 12 months ending in March 2019, the company's Zenatane (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg brand and generic had US sales of approximately USD525m MAT, according to IQVIA Health.
In addition, the company's Zenatane (Isotretinoin Capsules, USP) are available in 3x10 (30-count) blister packages of 10 mg, 20 mg 30 mg, and 40 mg Capsules, USP.
Amerigen wins US FDA approval for generic Penicillamine in 250 mg capsules
Amerigen Pharmaceuticals Limited wins US FDA approval for Penicillamine Capsules USP in 250 mg
Dr. Reddy's Laboratories Launches Testosterone Gel, 1.62% in the US Market
Teva Provides Update on Fremanezumab Clinical Development for Use in Episodic Cluster Headache
Teva Launches Generic Version of VESIcare Tablets in the United States
Teva Pharmaceutical begins US launch of generic VESIcare tablets
Oakrum Pharma signs product development and commercialisation partnership with Biophore
Teva Pharmaceutical launches generic version of VESIcare tablets in the US
Phyton Biotech and AqVida receive European approval for paclitaxel injectable FDF
The United States Food and Drug Administration approves Narcan
Teva Signs New USD 2.3bn Syndicated Revolving Credit Facility
Endo announces delivery of authorised generic PROVENTIL (albuterol sulfate) in the US